ORKA (Oruka Therapeutics) Inventories, Work In Process: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORKA Oruka Therapeutics Inc ORKA
14 GF Score
Price $90.88
! 3 Warning Signs
View Full Analysis

What is Oruka Therapeutics Inventories, Work In Process?

Oruka Therapeutics ORKA -1.38% 14 Inventories, Work In Process is $0.00 Mil as of Mar. 2026. GuruFocus rates ORKA with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Oruka Therapeutics's work in process for the quarter that ended in Mar. 2026 was $0.00 Mil.

Oruka Therapeutics Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Oruka Therapeutics's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oruka Therapeutics Inventories, Work In Process Chart

Oruka Therapeutics Annual Data
Trend Dec24 Dec25
Inventories, Work In Process
0.00 0.00

Oruka Therapeutics Quarterly Data
Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
ORKA
14GF Score
Oruka Therapeutics Inc ORKA
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oruka Therapeutics Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of $0.00 Mil mean?
Oruka Therapeutics (ORKA) has a Inventories, Work In Process of $0.00 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Oruka Therapeutics and its competitors.
Is Oruka Therapeutics' Inventories, Work In Process too high?
Oruka Therapeutics' current Inventories, Work In Process is $0.00 Mil. Overall, Oruka Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Oruka Therapeutics' Inventories, Work In Process compare to DNTH and SRRK?
Oruka Therapeutics' Inventories, Work In Process of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Oruka Therapeutics and its competitors. Oruka Therapeutics's current Inventories, Work In Process is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oruka Therapeutics stock overvalued right now?
Oruka Therapeutics (ORKA) has a current Inventories, Work In Process of $0.00 Mil. The current Inventories, Work In Process is $0.00 Mil. Oruka Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Oruka Therapeutics (ORKA), the current Inventories, Work In Process is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oruka Therapeutics Business Description

Other Exchanges HQ1:Germany
Address 855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
14GF Score

Get the complete analysis for ORKA

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.88
Price